Drugs / Stempeucel®
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00883727 | Apr 2009 → May 2010 | myocardial infarction | Stempeutics Research Pvt Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01453738 | Nov 2011 → Nov 2014 | osteoarthritis, knee | Stempeutics Research Pvt Ltd | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05854615 | Jan 2024 → Oct 2027 expected | limb ischemia, thromboangiitis obliterans | Cell Biopeutics Resources Sdn Bhd | Recruiting | No outcome recorded |
| Phase 4 | NCT05854641 | Jan 2024 → Oct 2027 expected | limb ischemia, peripheral arterial disease | Cell Biopeutics Resources Sdn Bhd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Stempeucel | “Objectives: To observe the efficacy and safety of Stempeucel® (adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells) in Malaysian patients...” NCT05854615 ↗3“Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel®): preclinical and clinical trial in osteoarthritis...” PMID 27993154 ↗ Dec 2016 “investigational new drug named Stempeucel” PMID 25484310 ↗ Dec 2014 |
| Modality | Cell therapy | “Cell therapy is promising as an exploratory cardiovascular therapy.” PMID 25484310 ↗ Dec 2014 |
| Route | Intravenous | “intravenous Stempeucel” PMID 25484310 ↗ Dec 2014 |